The Life of Dr. Shiva GopalVasishta

The world of healthcare is changing rapidly in a number of ways. A lot of people today are excited about what is going on in the world. However, with those changes, now is the time to try and make a difference in the lives of other people. If you are ready to try and take your life to a new level, now is the time to do so. With all of the technology that is available today, it should be easier than ever to monitor your health and have success over time in doing so. However, a lot of people today still struggle in this endeavor. A lot of people are excited about what the future holds with Dr. Shiva GopalVasishta in the world of healthcare.

Diet

One of the biggest issues for brain health is your diet. A lot of people only think about their diet from the perspective of looking good. However, what you eat is going to determine how much you are able to retain mentally in a variety of different ways. There are a lot of people who are ready and willing to see what is going on in this area. Not only that, but you can start to see the ways in which your diet is going to make an impact on your life in the future. Dr. Shiva GopalVasishta encourages people to eat a certain way in order to maintain brain health over the long term. This is a huge step that people can start taking today in order to have success.

Final Thoughts

Overall, now is the time to start working towards the future on your health. If you want to have the best health possible, you need to work with someone like Dr. Shiva GopalVasishta who can assist you in this area.

 

The Magic of Dr. Shiva Gopal Vasishta

According to a recent NIH Study, stem-cell transplants remain the next big thing in combating multiple sclerosis. In addition, research has shown that stem cell transplants of a patient’s own blood cells yielded long-term remission of common MS symptoms. Also, the treatment remains known as high-dose immunosuppressive therapy. It also remains known as the autologous hematopoietic cell transplant (HDIT/HCT). Furthermore, the results of the treatment remain astounding. According to the findings of the study, 69% of study participants experienced no progression of symptoms.

Also, the patients did not exhibit relapse or new formation of brain lesions. This includes a five-year period of a one-time treatment. Although further research remains necessary, it seems as though this single treatment remains more effective than other MS treatments. An additional study looked at HDIT/HCT in 24 clinical subjects ranging from the ages of 26 to 52 years of age. In spite of being under treatment for MS, their condition continued to worsen.

Furthermore, HDIT/HCT was able to help 70% of people who took it. Therefore, it may become the preferred option for patients who did not respond to other treatments. Of all neurologists and psychiatrists in New, Jersey, few can compare with Dr. Shiva Gopal Vasishta. Aside from being a staff member of the Kennedy University of Hospital, Dr. Shiva Gopal Vasishta hails from an educated background. In fact, he graduated from the Government Medical College in Nagpur in 1979. Furthermore, he finished his post-graduate medical education degree at Boston City Hospital.

Moreover, he specializes in Psychiatry. With that being said, Dr. Shiva Gopal Vasishta accepts numerous health plans such as Aetna, Medicare and Horizon Blue Cross Blue Shield. In addition to his impressive background in Myopathy, ALS Disease and EEG Testing, Dr. Shiva Gopal Vasishta remains board certified in Neurology.

JeanMarie Guenot, Exceptional President and CEO of a Biotechnology Conglomerate

Amphivena Therapeutics, Inc., founded in 2013 and based in San Francisco, is an innovative company that is happy to be led by its President and CEO, Dr. JeanMarie Guenot, due to her extensive experience, her passion for her life’s work, and her determination to help the developer of immune therapies for the treatment of cancer in its quest to eradicate blood cancers and restore cellular balance.

 

It is Amphivena’s belief that when blood forms, functions, and circulates properly, the body’s immune system will destroy tumors and their precursors. Their committed goal is to give patients suffering from hematologic malignancies such as leukemia the best available treatment options.

 

Dr. JeanMarie Guenot acquired her Ph.D at the University of California, San Francisco, one of the world’s leading universities in health sciences, and her MBA from the prestigious Wharton School at the University of Pennsylvania. She has 20 years of experience in the pharmaceutical and biotechnology industries and in building and rebuilding companies.

 

As her Facebook page indicates, Jeanmarie’s scientific career began as the preclinical R&D principal scientist at Hoffmann-La Roche, where she helped to develop drugs for oncology, autoimmune diseases, metabolic diseases, and inflammation. In addition, through her own company, Guenot LLC, she provides specialized consultation services for pharmaceuticals and biotechnology companies relative to commercial planning, project and finance management, venture capital, mergers, and acquisitions.

 

Before Amphivena, Dr. Guenot served in various companies in different roles included being the business consultant for Hoffmann in Shangai and Basel for one year and the vice-president of Corporate and Business Development at PDL BioPharma, which led to a successful deal between PDL and Hoffmann-La Roche and PDL.

 

As an acknowledgment of her efforts, she received the Deal of Distinction Award in 2006 from the Licensing Executive Society and the Innovative Bio-Partnering Award from BioBusiness Network in 2005.  Read more about her accomplishments on Jeanmarie Guenot’s LinkedIn page: https://www.linkedin.com/in/jeanmarie-guenot-4a140617